Exclusion criteria: <br>1.Diagnosis of GIST or Kaposi sarcoma<br>2.Active central nervous system (CNS) or leptomeningeal metastasis (brain metastasis) at the time of enrollment. Participants with a history of a CNS metastasis previously treated with curative intent (for example, stereotactic radiation or surgery) that have not progressed on follow-up imaging, have been asymptomatic for at least 60 days and are not receiving systemic corticosteroids and or/anticonvulsants, are eligible. Participants with signs or symptoms of neurological compromise should have appropriate radiographic imaging performed before enrollment to rule out brain metastasis<br>3.Prior radiotherapy of the mediastinal/pericardial area or whole pelvis radiation<br>4.The participant has symptomatic congestive heart failure (CHF), or severe cardiac arrhythmia<br>5.The participant has unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction within 6 months of enrollment<br>6.The participant has a QTcB interval calculated using Bazett's formula interval of >450 milliseconds (msec) for males and >470 msec for females on screening electrocardiogram (ECG)<br>7.Females who are pregnant or breastfeeding<br>8.Known allergy to any of the treatment components including a history of allergic reactions attributed to compounds of chemical or biological composition similar to olaratumab, dexrazoxane or doxorubicin<br>9.The participant has a known active fungal, bacterial, or viral infection including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis (screening is not required)<br>10.Known history of active bleeding (defined as within 14 days of first dose of study drug) or pathological condition that carries a high risk of bleeding (for example, tumor involving major vessels or known esophageal varices)<br>11.History of another primary cancer, with the exception of <br>i) curatively treated non-melanomatous skin cancer or ii) curatively treated cervical carcinoma in situ or iii) other primary nonhaematologic malignancies or solid tumor treated with curative intent, no known active disease and no treatment administered during the last 3 years prior to enrollment<br>12.Electively planned or required major surgery during the course of the clinical trial<br>13.Any condition that, in the opinion of the investigator, would compromise the well-being of the participant or the study or prevent the participant from meeting or performing study requirements<br>14.On-treatment participation in another clinical study in the period 30 days prior to start of study treatment and during the study<br>15.Legal incapacity or limited legal capacity.<br>16.Any condition that requires concomitant vaccination with yellow fever vaccine<br><br>